What is the price of zomedica stock now?
Since then, ZOM stock has increased by 41.2% and is now trading at $0.2935. View which stocks have been most impacted by COVID-19. When is Zomedica's next earnings date?
Will zomedica stock outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe ZOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days. Zomedica does not currently pay a dividend. Zomedica does not have a long track record of dividend growth.
Is zomedica (Zom) stock a roller-coaster ride?
Suffice it to say, ZOM stock has taken its traders on a wild roller-coaster ride. Source: Postmodern Studio / Shutterstock.com Zomedica is a company that’s trying to save animals’ lives and make the world a better place. At the same time, the company’s stock has wreaked havoc on some traders, while enriching
Will zomedica's valuation justify its potential?
But, to justify its valuation, Zomedica will need to capture a pretty large share of this market, which is set to be worth $2.8 billion per year in sales by 2024.InvestorPlace - Stock Market News, Stock Advice & Trading Tips So, weighing potential versus valuation, what’s the best move for investors looking to enter the stock today? Take your time.
Where does Zomedica trade?
What is Zomedica Corp?
What is MarketBeat community ratings?
What is the P/E ratio of Zomedica?
Is there enough data for Zomedica?
Does Zomedica pay dividends?
See more
About this website
Why is Zomedica stock dropping?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
What happen to Zomedica stocks?
Zomedica's shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner's delays. Zomedica could rebound once new assays for its Truforma instrument are available.
Should I sell my Zomedica stock?
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Sell'.
Is ZOM expected to go up?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +430.74% increase from the last price of 0.23.
Will Zomedica be delisted?
(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.
What is Zomedica target price?
$1.20Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.25
Is Zomedica a good investment?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Is Sundial growers a buy?
Following the Q3 earnings report, Sundial shares experienced a strong rally. However, even though SNDL is worth just over 50 cents and is under pressure to pass the $1-per-share level to remain in compliance with Nasdaq, here are three reasons why buying the stock ahead of earnings could be a good deal.
Will Zomedica stock recover?
There is potential for a short term uptick in the Zom stock price, especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time. A mild divergence also supports the notion of a slight recovery in the Zom stock price in the near term.
How many shares of ZOM are there?
Share StatisticsAvg Vol (3 month) 319.74MShares Outstanding 5979.9MImplied Shares Outstanding 6N/AFloat 8966.83M% Held by Insiders 12.56%7 more rows
Is ZOM on Nasdaq?
Common Shares (ZOM) Stock Price, Quote, News & History | Nasdaq....Key Data.LabelValueToday's High/Low$0.25/$0.23Share Volume25,146,334Average Volume45,836,596Previous Close$0.219113 more rows
How has Zomedica's stock price performed in 2022?
Zomedica's stock was trading at $0.3201 at the beginning of the year. Since then, ZOM shares have decreased by 22.8% and is now trading at $0.2470....
Are investors shorting Zomedica?
Zomedica saw a increase in short interest in May. As of May 15th, there was short interest totaling 112,640,000 shares, an increase of 23.4% from t...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per s...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica updated its FY 2021 earnings guidance on Monday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. Th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Mr. Larry C. Heaton II , Pres & CEO (Age 65, Pay $488k) Ms. Ann Marie Cotter CPA , CF...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Amneal Pharmaceuticals (AMRX) , Amneal Pharmaceuticals (AMRX) , Aclaris Therapeutics (ACRS)...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.14%), Stat...
ZOMEDICA STOCK FORECAST 2022, 2023, 2024
Zomedica share price predictions and forecast for 2022, 2023, 2024. There are predicted maximum, minimum and close prices for each month. Zomedica stock price outlook. ZOM
Zomedica Price Target, Predictions & Analyst Ratings
The current Zomedica (NYSEAMERICAN:ZOM) price target is $0.00. Learn why top analysts are making this price prediction at MarketBeat.
ZOM - Zomedica Corp Forecast - CNNMoney.com
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20.
Zomedica Corp. (ZOM) Latest Stock News & Headlines - Yahoo!
Get the latest Zomedica Corp. (ZOM) stock news and headlines to help you in your trading and investing decisions.
ZOM Zomedica Corp — Stock Price and Discussion | Stocktwits
Real-time trade and investing ideas on Zomedica Corp ZOM from the largest community of traders and investors.
How many shares were in Zomedica on Nov 12?
How much did Baskin pay for Zomedica?
On Nov. 12, the volume in Zomedica stock was about 15.8 million shares. Given that ZOM traded at about eight cents that day, we’re looking at total dollar trading in the range of $1 million. On Nov. 13, however, ZOM saw volume of over 253 million shares.
How much is the diagnostic market for companion animals?
Someone paid Baskin $299 to tout Zomedica on video-sharing platform Cameo. In response, the stock rose 171% over the two sessions. The Good News Admittedly, a long-term investor can look at Zomedica and see some reason for optimism, though.
How much is AMC worth in 2020?
The entire diagnostic market for companion animals should reach about $2.8 billion globally by 2024, according to Zomedica itself. The company is targeting only a tiny slice of that market. And yet, Zomedica now has a market capitalization of $1.56 billion.
Is Zomedica the next IDEXX?
At the beginning of 2020, before the novel coronavirus pandemic hit, AMC was worth less than $1 billion. In fact, even with the balance sheet moves, AMC now has a higher enterprise value (market capitalization plus net debt) than it did at the beginning of 2020. It’s hard to see how that makes sense.
Is GameStop going to rebound in 2021?
Zomedica has a lot of work ahead of it before it’s even close to becoming the next IDEXX. In the meantime, the company still needs to execute the commercialization of Truforma. If it experiences any hiccups along the way, shares could fall back to lower price levels. Reconsider ZOM stock as a buy if that happens.
Is Baskin paid to promote the stock?
In fact, bulls argued, they were a sign of the end of the console cycle. With new consoles coming from Sony (NYSE:SNE) and Microsoft (NASDAQ:MSFT), earnings would quickly rebound in 2021 and beyond.
Who is Zomedica Corp?
While it turns out Baskin was paid to promote the stock, there is another upcoming and more tangible catalyst for investors to get behind; this is due to the upcoming launch of Truforma, Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs.
How much will the pet diagnostics market be in 2024?
ANN ARBOR, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, today announced that it had acquired the Pulse Veterinary Technologies businesses for $70.9 million in an all-cash, stock transaction. Pulse Veterinary Technologies (“PulseVet”) is a world leader in electro-hydraulic shock wave technology for the treatment of a wide vari
Is Zomedica in the development stage?
consumers were expected to have spent $99 billion on their pets in 2020. The companion animal diagnostics market is forecast to reach $2.8 billion by 2024, at a compounded annual growth rate (CAGR) of 9.8% from 2019 to 2024.
Is Zomedica publicly traded?
Zomedica, which is in the development stage, recorded no revenues in 2020. The 2020 net loss resulted from research and development (“R&D”) expenses of approximately $8.0 million, general and administrative (“G&A”) expenses of approximately $6.0 million, and professional fees of approximately $2.2 million.
Is Zomedica a meme?
Founded in 2013 and publicly-traded since 2016, Zomedica (ZOM) is a relatively new organization. However, this veterinary-focused medical device company has seen tremendous interest among growth investors of late. Why? Well, there are a number of reasons for this. Among the core reasons for the surging interest in pet-friendly tech plays is the growth we've seen in pet adoption rates throughout the pandemic. As owners are discovering, a pet adoption is a multi-year (or even multi-decade) long co
Why did Zomedica go down 60%?
As has been the case for several months, Zomedica (NYSEAMERICAN:ZOM) continues to tread water. ZOM stock, a pet diagnostics play and reputed meme stock, has struggled to bounce back after big declines last spring. Source: Postmodern Studio / Shutterstock.com Said decline came right after shares, trading for well under $1 at the start of 2021, zoomed to as much as $2.91. The move may or may not have been the product of Reddit traders stampeding into it with full force. But I wouldn’t put too much
What is Zomedica's core product?
Zomedica went on a 60% slide over the next month. This appears to be largely due to issues the company saw with its rollout.
How much is the diagnostics market worth in 2021?
Zomedica's core product, its TRUFORMA in-clinic biosensor diagnostics platform, is the key driver that investors in ZOM look to for growth.
Is Zomedica still making revenue in 2020?
Estimates are that this market will grow from an estimated valuation of $2.5 billion in 2021 to a projected value of $3.9 billion in 2026.
Is Zomedica paying for an expanded sales organization?
Zomedica had no revenue in 2020. This is because it is still in the early stages of commercializing its TRUFORMA product. In March, Zomedica did see the first commercial sales of its TRUFORMA system. However, the company's share price declined alongside the company's commercialization ramp up, for various reasons.
Is Zomedica a meme?
Zomedica anticipates that the issues will be resolved by the end of this year. But meanwhile, it is paying for an expanded sales organization that is majorly spinning its wheels. Accordingly, it's hard to look at Zomedica's recent results positively.
What is Stock Sentiment?
Zomedica is a company that has lost its luster, at least in terms of being considered a meme stock. Any sort of positive momentum the company had earlier this year appears to have waned.
More About Zomedica Corp
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Who is the CEO of Zomedica?
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health.
When will Zomedica be available for dogs?
Zomedica's ascent began in January of this year, when it announced the arrival of a new CEO, Robert Cohen. Shortly thereafter, Reddit traders piled into the stock, causing it to grow explosively and putting it on the map for the first time.
How much cash does Zomedica have in 2021?
The biggest reason why people are talking about Zomedica right now is that Truforma is scheduled to launch on March 30. At launch, it'll be capable of five different diagnostic assays for cats and dogs. Two more assays will be out the door by the end of 2021.
How much will companion animal diagnostics cost in 2024?
Zomedica went overboard with stock issuance and as a result, it had cash and cash equivalents of $276.6 million as of March 31, 2021. The stock issuance was done at a higher price than what ZOM currently trades at.
Is Zom stock bullish?
In its filing, citing data from MarketsandMarkets, Zomedica said that the market opportunity for companion animal diagnostics is expected to rise from $1.7 billion in 2019 to $2.8 billion in 2024. Source: Zomedica Facebook. Article continues below advertisement.
Will Zom stock rise in 2021?
ZOM stock has crossed above its 50-day SMA (simple moving average), which is a bullish indicator. On the downside, the 200-day SMA has been strong support for the stock.
Is Zom a pre-revenue company?
ZOM stock could rise more from these levels. The rise in the stock hasn’t been speculative like it was in the first quarter of 2021. The stock has been going up as the company advances to scale up its capabilities to commercialize Truforma. Overall, I expect the rally in ZOM stock to continue.
Is a short squeeze happening in ZOM stock?
While the revenues aren't much, it signals that ZOM isn't a pre-revenue company. If the Truforma product can gain traction in the market, better days could lie ahead for Zomedica stock. The market for pet care is growing fast, which bodes well for Zomedica.
Where does Zomedica trade?
ZOM stock has gained 22.9 percent over the last 10 days. This has left many investors wondering whether a short squeeze 2.0 is happening in the stock. According to data from Fintel, over 50 million shares of ZOM stock were sold short on June 3, which was 35 percent of the trading volume on that day.
What is Zomedica Corp?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
What is MarketBeat community ratings?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
What is the P/E ratio of Zomedica?
MarketBeat's community ratings are surveys of what our community members think about Zomedica and other stocks. Vote “Outperform” if you believe ZOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Is there enough data for Zomedica?
The P/E ratio of Zomedica is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Zomedica pay dividends?
There is not enough analysis data for Zomedica.